High Prevalence of Abnormal Circadian Blood Pressure Regulation and Impaired Glucose Tolerance in Adults with Hypopituitarism

Abstract

Patients with hypopituitarism have an increased mortality from cardiovascular events. Reduced nocturnal blood pressure decline (non-dipping) and impaired glucose tolerance are considered as cardiovascular risk factors. To evaluate the role of these risk factors in patients with hypopituitarism we determined the 24-hour blood pressure regulation and glucose tolerance status in hypopituitary patients with and without growth hormone (GH) deficiency. Sixty-one hypopituitary subjects 5 ± 3 years after brain surgery because of macroadenoma, 61 patients with type 2 diabetes mellitus (T2DM), and 20 healthy controls were included. Forty-four hypopituitary patients were GH deficient and 28 of these on GH treatment. Non-dipping was observed in 41 % (n = 7) of hypopituitary subjects with normal GH release, in 46 % (n = 13) of patients on GH therapy, and in 69 % (n = 11) of untreated GH deficient patients. Untreated GH deficient patients had a higher systolic night/day ratio (1.00 ± 0.03) compared to non GH deficient (0.92 ± 0.02; p < 0.02) and GH treated hypopituitary patients (0.93 ± 0.01; p < 0.02). The rate of non-dipping in hypopituitarism was comparable to that in T2DM. Pathologic glucose tolerance was diagnosed in 30 % of the hypopituitary patients. The prevalence of non-dipping was independent of glucose metabolism in hypopituitary patients. All controls had normal night time blood pressure fall and glucose metabolism. The high prevalence of nocturnal non-dipping and glucose intolerance detected in this cohort might contribute to the increased cardiovascular risk of hypopituitary patients.

Key words

Hypopituitarism - non-dipping - glucose metabolism

References

• 1 ADA . Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus.  Diabetes Care. 2002;  25 S5-S20
• 2 Balkau B, Shipley M, Jarrett R J, Pyorala K, Pyorala M, Forhan A, Eschwege E. High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men. 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study.  Diabetes Care. 1998;  21 360-367
• 3 Borson-Chazot F, Serusclat A, Kalfallah Y, Ducottet X, Sassolas G, Bernard S, Labrousse F, Pastene J, Sassolas A, Roux Y, Berthezene F. Decrease in carotid intima-media thickness after one year growth hormone (GH) treatment in adults with GH deficiency.  J Clin Endocrinol Metab. 1999;  84 1329-1333
• 4 Bramnert M, Segerlantz M, Laurila E, Daugaard J R, Manhem P, Groop L. Growth hormone replacement therapy induces insulin resistance by activating the glucose-fatty acid cycle.  J Clin Endocrinol Metab. 2003;  88 1455-1463
• 5 Bülow B, Hagmar L, Eskilsson J, Erfurth E M. Hypopituitary females have a high incidence of cardiovascular morbidity and an increased prevalence of cardiovascular risk factors.  J Clin Endocrinol Metab. 2000;  85 574-584
• 6 Bülow B, Hagmar L, Mikoczy Z, Nordstrom C H, Erfurth E M. Increased cerebrovascular mortality in patients with hypopituitarism.  Clin Endocrinol (Oxf). 1997;  46 75-81
• 7 Elhadd T A, Abdu T A, Oxtoby J, Kennedy G, McLaren M, Neary R, Belch J J, Clayton R N. Biochemical and biophysical markers of endothelial dysfunction in adults with hypopituitarism and severe GH deficiency.  J Clin Endocrinol Metab. 2001;  86 4223-4232
• 8 Equiluz-Bruck S, Schnack C, Kopp H P, Schernthaner G. Nondipping of nocturnal blood pressure is related to urinary albumin excretion rate in patients with type 2 diabetes mellitus.  Am J Hypertens. 1996;  9 1139-1143
• 9 Gibney J, Wallace J D, Spinks T, Schnorr L, Ranicar A, Cuneo R C, Lockhart S, Burnand K G, Salomon F, Sonksen P H, Russell-Jones D. The effects of 10 years of recombinant human growth hormone (GH) in adult GH-deficient patients.  J Clin Endocrinol Metab. 1999;  84 2596-2602
• 10 Jeffcoate W. Growth hormone therapy and its relationship to insulin resistance, glucose intolerance and diabetes mellitus: a review of recent evidence.  Drug Saf. 2002;  25 199-212
• 11 Johnston D G, Beshyah S A, Markussis V, Shahi M, Sharp P S, Foale R A, Skinner E M. Metabolic changes and vascular risk factors in hypopituitarism.  Horm Res. 1992;  38 (Suppl 1) 68-72
• 12 Markussis V, Beshyah S A, Fisher C, Sharp P, Nicolaides A N, Johnston D G. Detection of premature atherosclerosis by high-resolution ultrasonography in symptom-free hypopituitary adults.  Lancet. 1992;  340 1188-1192
• 13 Matsumura K, Abe I, Fukuhara M, Fujii K, Ohya Y, Okamura K, Fujishima M. Modulation of circadian rhythm of blood pressure by cortisol in patients with hypopituitarism.  Clin Exp Hypertens. 1994;  16 55-66
• 14 O'Brien E, Sheridan J, O'Malley K. Dippers and non-dippers.  Lancet. 1988;  2 397
• 15 Pfeifer M, Verhovec R, Zizek B. Growth hormone (GH) and atherosclerosis: changes in morphology and function of major arteries during GH treatment.  Growth Horm IGF Res. 1999 a;  9 (Suppl A) 25-30
• 16 Pfeifer M, Verhovec R, Zizek B, Prezelj J, Poredos P, Clayton R N. Growth hormone (GH) treatment reverses early atherosclerotic changes in GH-deficient adults.  J Clin Endocrinol Metab. 1999 b;  84 453-457
• 17 Rosen T, Bengtsson B A. Premature mortality due to cardiovascular disease in hypopituitarism.  Lancet. 1990;  336 285-288
• 18 Sturrock N D, George E, Pound N, Stevenson J, Peck G M, Sowter H. Non-dipping circadian blood pressure and renal impairment are associated with increased mortality in diabetes mellitus.  Diabet Med. 2000;  17 360-364
• 19 Svensson J, Bengtsson B-A. Growth hormone replacement therapy and insulin sensitivity.  J Clin Endocrinol Metab. 2003;  88 1453-1454
• 20 Tomlinson J W, Holden N, Hills R K, Wheatley K, Clayton R N, Bates A S, Sheppard M C, Stewart P M. Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group.  Lancet. 2001;  357 425-431
• 21 Verdecchia P, Porcellati C, Schillaci G, Borgioni C, Ciucci A, Battistelli M, Guerrieri M, Gatteschi C, Zampi I, Santucci A. Ambulatory blood pressure. An independent predictor of prognosis in essential hypertension.  Hypertension. 1994;  24 793-801
• 22 Verdecchia P, Schillaci G, Guerrieri M, Gatteschi C, Benemio G, Boldrini F, Porcellati C. Circadian blood pressure changes and left ventricular hypertrophy in essential hypertension.  Circulation. 1990;  81 528-536
• 23 Verhelst J, Abs R. Long-term growth hormone replacement therapy in hypopituitary adults.  Drugs. 2002;  62 2399-2412
• 24 White W B. Relevance of blood pressure variation in the circadian onset of cardiovascular events.  J Hypertens Suppl. 2003;  21 (Suppl 6) S9-15